Mounjaro vs Zepbound: What Actually Decides Which One You Get

Wait — are Mounjaro and Zepbound actually the same drug?

Yes, completely. Both are tirzepatide, manufactured by Eli Lilly, sold at the same six dose strengths — 2.5mg, 5mg, 7.5mg, 10mg, 12.5mg, 15mg — in the same style of prefilled pen or single-dose vial. There is no formulation difference between what's in a Mounjaro pen and what's in a Zepbound pen at a matched dose. The two names exist because Lilly ran two separate FDA approval processes for two separate uses. Mounjaro was approved in May 2022 for type 2 diabetes. Zepbound followed in November 2023, approved specifically for chronic weight management, and picked up a second approved use in December 2024 for moderate-to-severe obstructive sleep apnea in adults with obesity — worth knowing at 40-plus, since sleep apnea risk climbs as estrogen declines through perimenopause, often alongside the weight shift that brings someone to this page in the first place.

If what you're actually trying to sort out is tirzepatide against a genuinely different drug — not two names for the same one — this isn't that page. Semaglutide vs tirzepatide covers the real molecule-to-molecule comparison, and Mounjaro vs Ozempic does the same for those two specific diabetes brands. This page stays narrowly on the actual fork in the road: same drug, two labels, one decision about which one applies to you.

If it's the same drug, why are the price and coverage so different?

Insurance doesn't pay for molecules — it pays for approved uses. A pharmacy benefit manager checks the diagnosis code on your prescription against what a drug is FDA-labeled to treat, and that label, not the chemistry in the pen, is what a formulary is built around. A plan can cover Mounjaro for a documented type 2 diabetes diagnosis and deny the identical injection under the Zepbound name for a patient whose chart says obesity, or the reverse, depending entirely on which benefit category the plan writes obesity drugs into.

That's also why the manufacturer coupons don't cross over. Eli Lilly runs a separate savings card for each brand, tied to each brand's own approved use, and a Mounjaro coupon won't apply to a Zepbound fill even though Lilly issues both. Once you understand the split is entirely administrative — a labeling and billing distinction, not a clinical one — the rest of the price differences on this page stop looking arbitrary and start looking like what they are: downstream effects of one FDA decision made years apart for the same medicine.

Which one will your doctor actually prescribe you — and can you ask for the other?

In practice, the diagnosis on your chart tends to decide it before cost or coverage even enters the conversation. A documented type 2 diabetes diagnosis, or an A1C clearly in diabetic range, points a prescriber toward Mounjaro, since that's the label the drug was built for and the one insurance is most likely to recognize. A documented obesity diagnosis, or a lower BMI paired with a weight-related condition, points toward Zepbound. Where it gets genuinely off-script: prescribing Mounjaro off-label for weight loss is common enough in practice — some clinicians reach for it specifically when a patient's plan already covers Mounjaro but excludes Zepbound, or when supply or cost makes it the more practical choice even without a diabetes diagnosis to justify it.

This is exactly the gap a lot of women in their 40s and 50s fall into. Perimenopause pushes insulin resistance and abdominal fat redistribution in a way that can land someone with an A1C in the prediabetes range and a waistline that's genuinely changed, without either number quite clearing a formal diagnosis threshold. She's not diabetic enough for Mounjaro's on-label use, and she may not be heavy enough — or lack the specific weight-related comorbidity — for Zepbound's. That's not a reason to assume you're stuck; it's a reason to ask your prescriber directly which label actually fits your labs and your chart, rather than accepting whichever name happens to come up first in the visit.

And yes, you can ask for the other one. What changes is what you're eligible for once you do: a prescription written to match Zepbound's obesity or sleep-apnea label opens up Zepbound's savings card and LillyDirect self-pay tiers; a prescription that documents genuine type 2 diabetes opens up Mounjaro's card and, if you're uninsured, Lilly Cares. Asking a clinician who treats midlife women's metabolic health specifically — rather than a generalist who may not think to check both angles — is often the more useful move than trying to steer the prescription yourself. Midi Health is one option built around exactly that combination of hormonal and metabolic care.

Mounjaro vs Zepbound cost: what will each one actually cost you?

The price table above lines up the six real paths side by side, checked as of early August 2026. The short version: if you're commercially insured and your chart matches the label you're being billed under, both drugs can land around $25 a month through their respective savings cards. Outside of that, the paths diverge sharply, and the gap has less to do with which brand you're holding than with whether your diagnosis matches the paperwork behind it.

Mounjaro's own retail price, with no discount applied, runs about $1,080 a month at list price at a US pharmacy (a GoodRx coupon lands around $1,060 to $1,090) — and unlike Zepbound, there's no manufacturer self-pay vial program to undercut that number if you're uninsured. Lilly built that cash-pay infrastructure under the Zepbound name instead: self-pay vials through LillyDirect start at $299 a month — genuinely lower than what an uninsured Mounjaro patient is stuck paying at full retail, even though it's the identical injection (see the table above for the full dose ladder). For the complete breakdown behind each brand, see Mounjaro cost and Zepbound cost.

One more asymmetry worth knowing before you assume the cheapest number applies to you: Lilly Cares Foundation, the company's charitable assistance program, has a real record of providing Mounjaro free to income-qualified, uninsured patients with a documented type 2 diabetes prescription. Zepbound isn't on that same covered-medication list. If you're uninsured and your diagnosis is genuinely diabetes, Lilly Cares is worth applying to directly — if your diagnosis is obesity, that specific door isn't open, and LillyDirect's self-pay tier is the realistic floor instead. Mounjaro savings and Zepbound savings go deeper on both programs' fine print, and Mounjaro cheapest and Zepbound cheapest rank every verified price we track for each brand.

Does Medicare or my commercial plan actually cover either one?

This is where the indication gap has the most teeth. Standard Medicare Part D can cover Mounjaro the ordinary way — as a diabetes medication on a plan's formulary — for a beneficiary with a genuine type 2 diabetes diagnosis, subject to whatever cost-sharing that plan sets. Medicare has historically been barred by statute from covering a drug prescribed solely for weight loss, which meant Zepbound, prescribed for obesity, got no Medicare help at all for most of its time on the market.

That changed narrowly in 2026. A CMS pilot called the Medicare GLP-1 Bridge, running from July 1, 2026 through the end of 2027, lets eligible Part D beneficiaries fill the Zepbound KwikPen for a flat $50 monthly copay — but only the KwikPen, not the single-dose vial, and only for beneficiaries who meet BMI or related health-condition criteria the program sets. It's a genuinely new pathway, not a workaround of the old rule, and it's specific to Zepbound rather than something that also opens up Mounjaro coverage for weight loss.

Commercial coverage varies by employer and plan design for both drugs, and a documented diagnosis matching the label you're billing under remains the thing prior-authorization reviewers actually check. If neither path applies to you, Mounjaro without insurance and Zepbound without insurance walk through every cash-pay option in more depth than fits here.

Is the dose and titration schedule the same for both?

Yes, identically. Both start at 2.5mg, both climb through the same intermediate steps, and both top out at a 15mg maximum, on the same once-weekly injection schedule regardless of which name is on the box. Nothing about switching brands changes how your dose is expected to progress — the ladder belongs to the molecule, not the label. For the full step-by-step schedule, see tirzepatide dosage.

Is there any real difference in side effects between the two?

No — same molecule, same underlying mechanism, same family of side effects. Nausea, constipation, diarrhea, and the general slowdown in digestion that drives all of them show up at broadly similar rates whether the pen says Mounjaro or Zepbound, because the active ingredient triggering them is identical. Where people report a difference, it usually traces back to which dose they're actually on rather than which brand name is printed on the box. The full rundown of what to expect and when it typically eases lives at tirzepatide side effects.

Can you switch from Mounjaro to Zepbound — or the other way around?

Routinely, and for a few specific, practical reasons rather than any clinical need to change medications. Pharmacy substitution between the two brands became common during the shortage years, when whichever brand was actually in stock at a given pharmacy sometimes decided what got dispensed. An insurance-driven switch is just as common now: a plan starts covering Zepbound for obesity but not Mounjaro, or the reverse, and a prescriber rewrites the script to match whichever brand the plan will actually pay toward. And a genuine new type 2 diabetes diagnosis surfacing after months on Zepbound is a real, if less common, reason a prescriber might add or switch to Mounjaro specifically for that indication and its own coupon.

Mechanically, it's a simple swap rather than a real transition — because the dose ladder is identical between the two brands, there's no re-titration or dose-equivalency question the way there is switching between genuinely different molecules. What's worth confirming with your pharmacist is administrative, not clinical: whether a savings-card enrollment or refill-timing window carries over when the brand name on the prescription changes, since each card's terms are tracked separately.

Mounjaro or Zepbound — which should you actually ask for?

• You have a documented type 2 diabetes diagnosis and commercial insurance: Mounjaro is the on-label choice, and the Mounjaro Savings Card is the cheapest path if your plan already covers it — ask specifically whether it's on formulary rather than assuming.
• Your goal is weight management and you're insured: Zepbound is the on-label choice, since it's the brand actually built for that use — a Mounjaro prescription written off-label for weight loss won't qualify for Mounjaro's own coupon or for Lilly Cares.
• You're uninsured and paying cash, regardless of diagnosis: Zepbound through LillyDirect self-pay is the lower real number, since Mounjaro has no equivalent self-pay vial program of its own — worth asking your prescriber whether your chart can honestly support the Zepbound label even if diabetes is technically the bigger concern.
• Your labs sit in the perimenopausal gray zone — a rising A1C without a formal diabetes diagnosis, weight changes without a qualifying BMI or comorbidity: this is the profile most worth a direct conversation with your prescriber about which label your chart actually supports, since neither brand's savings program will approve a prescription that doesn't match its FDA-approved use on paper.

What about compounded tirzepatide instead of either brand?

It sits underneath both, cash-pay and without the brand-name coupon system attached to either Mounjaro or Zepbound — Curex currently runs the lowest verified all-in price for compounded tirzepatide at roughly $199 a month. It's not a discount version of either brand, though: compounded tirzepatide is prepared by a licensed 503A pharmacy rather than manufactured and FDA-reviewed the way both Mounjaro and Zepbound are, and it's legally available now only on a narrower basis than during the shortage years. That whole comparison — brand versus compounded, not brand versus brand — is covered in full at Zepbound vs. tirzepatide and compounded tirzepatide providers, including Henry Meds and Mochi Health alongside Curex, so it isn't worth re-deriving here.